Intravenous Administration of REOLYSIN® for Patients with Metastatic Melanoma
In August 2008, Oncolytics announced that the US National Cancer Institute (NCI) had started enrollment in a Phase II trial for patients with metastatic melanoma using systemic administration of REOLYSIN®. Patients would receive systemic administration of REOLYSIN® at a dose of 3 x 1010 TCID50 per day on days one through five of each twenty-eight day cycle, for up to twelve cycles of treatment.
The primary objectives of the study were to assess the antitumor effects of REOLYSIN® in patients with metastatic malignant melanoma, as well as the safety profile of REOLYSIN®. Secondary objectives included assessment of progression free survival and overall survival.
The NCI sponsored the trial under its Clinical Trials Agreement with Oncolytics, while Oncolytics provided clinical supplies of REOLYSIN®. The Principal Investigator is Dr. Evanthia Galanis of the Mayo Clinic Cancer Center.
- August 7, 2012: Phase II Trial of Intravenous Administration of Reolysin® (Reovirus Serotype-3-dearing Strain) in Patients with Metastatic Melanoma (PDF)